Physician profile
Minzi Chen
NPI 1922269067
$2,810.95
in general payments reported to CMS, 2019-2025
12 companies · $893 in 2025
The $893 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $12.09 · 2021: $127 · 2022: $38.04 · 2023: $473 · 2024: $918 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $703.22 | 2019-2025 | Krystexxa, Tavneos, Otezla |
| Abbvie INC. | $415.19 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $391.67 | 2024-2025 | Bimzelx |
| Aurinia Pharma U.S., INC. | $293.62 | 2021-2025 | Lupkynis |
| Janssen Biotech, INC. | $242.91 | 2024-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $213.91 | 2019-2024 | Benlysta |
| Alexion Pharmaceuticals, INC. | $155.06 | 2022-2024 | Strensiq |
| Inspire Medical Systems, INC. | $108.79 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.97 | 2024 | |
| Genentech USA, INC. | $77.25 | 2019 | |
| Biotronik INC. | $53.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.58 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minzi Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.